medigraphic.com
ISSN 1561-302X (Impreso)

2016, Número 4

<< Anterior Siguiente >>

Rev cubana med 2016; 55 (4)


Importancia de indicar e interpretar las pruebas de autoanticuerpos

Kokuina E

Idioma: Español
Referencias bibliográficas: 62
Paginas: 324-339
Archivo PDF: 300.04 Kb.


RESUMEN

La aceptación y la relevancia de los autoanticuerpos se evidencia por su creciente incorporación en los criterios diagnósticos y de clasificación de las enfermedades autoinmunes. Una de las preocupaciones actuales, derivadas del uso ampliado de los autoanticuerpos, es la conservación del uso adecuado, en contraposición con el uso indiscriminado que genera un aumento de resultados falsos positivos que conducen a costosos errores en el diagnóstico, seguimiento, e incluso, tratamiento del paciente. Este artículo intenta resumir las circunstancias en que es oportuno ordenar las pruebas de autoanticuerpos, y cómo interpretarlas para preservar su utilidad clínica y refrenar los gastos de salud.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11:754-65.

  2. Tozzoli R, Sorrentino MC, Bizzaro N. Detecting multiple autoantibodies to diagnose autoimmune comorbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist. Immunol Res. 2013;56:425-31.

  3. Beck LH, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. Mtype phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11-21.

  4. Lancaster E, Dalmau J. Neuronal autoantigens-pathogenesis, associated disorders and antibody testing. Nat Rev Neurol. 2012;8:380-90.

  5. Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev. 2013;12:340-54.

  6. Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a metaanalysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014;13:883-91.

  7. Iaccarino L, Ghirardello A, Bettio S, Zen M, Gatto M, Punzi L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;(48- 49):122-7.

  8. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, Feist E, Burmester GR, et al. Antiphospholipid antibody profiling: time for a new technical approach? Autoimmun Rev. 2012;11:821-6.

  9. Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12:918-23.

  10. Damoiseaux J, Andrade LE, Fritzler MJ, Shoenfeld Y. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. Autoimmun Rev. 2015;14:555-63.

  11. Kokuina E, Estévez del Toro M, Gutiérrez Rojas A, Ortiz Labrada A, Sánchez Bruzón Y, Pérez Campos D, et al. Identificación de predictores serológicos de recaída en pacientes con lupus eritematoso sistémico: estudio prospectivo de 12 meses. Rev Cubana Med [serie en Internet]. 2016 [citado 6 de Noviembre de 2016];55(1). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75232016000100004&lng=es&nrm=iso&tlng=es

  12. Lock RJ. Rational requesting or rationing testing? J Clin Pathol. 2004;57:121-2.

  13. Kwok J, Jones B. Unnecessary repeat requesting of tests: an audit in a government hospital immunology laboratory. J Clin Pathol. 2005;58:457-62.

  14. Wiik AS, Bizzaro N. Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases It is all about the patient! Autoimmun Highlights. 2012;3:35-49.

  15. Monica Bhagat M, Sehra ST, Shahane A, Kwan M. Utility of immunologic testing in suspected rheumatologic disease. Curr Allergy Asthma Rep. 2014;14:405.

  16. Aggarwal A. Role of autoantibody testing. Best Pract Res Clin Rheumatol. 2014;28:907-20.

  17. Sinclair D, Saas M, Stevens J. The effect of asymptom related ''gating policy'' on ANCA requests in routine clinical practice. J Clin Pathol. 2004;57:131-4.

  18. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1-11.

  19. Gibelin A, Maldini C, MahrA. Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Goodpasture syndrome: Vasculitides with frequent lung involvement. Semin Respir Crit Care Med. 2011;32:264-73.

  20. Edgar JDM. The clinical utility of ANCA positivity. Ann Rheum Dis. 1996;55c:494-6.

  21. Jennette JC, Wilkman AS, Falk RJ. Diagnostic predictive value of ANCA serology. Kidney Int. 1998;53:796-8.

  22. Qaseem A, Alguire P, Dallas P, Feinberg LE, Fitzgerald FT, Horwitch C, et al. Appropriate use of screening and diagnostic tests to foster high-value, costconscious care. Ann Intern Med. 2012;156:147-9.

  23. Yazdany J, Schmajuk G, Robbins M, Daikh D, Beall A, Yelin E, et al. Choosing Wisely: The American College of Rheumatology's Top 5 List of Things Physicians and Patients Should Question. Arthritis Care Res. 2013;65:329-39.

  24. Sui M, Lin Q, Xu Z, Han X, Xie R, Jia X, et al. Simultaneous positivity for anti- DNA, anti-nucleosome and anti-histone antibodies is a marker for more severe lupus nephritis. J Clin Immunol . 2013;33:378-87.

  25. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:17-25.

  26. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, MedsgerTA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5.

  27. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res. 2012;64:475-87.

  28. Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol. 1996;23:2055-62.

  29. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999;17:615-20.

  30. Miyakis S, Lockshin MD, Atsumi T, Branch DC, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.

  31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-81.

  32. Watts R. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritisnodosa for epidemiological studies. Ann Rheum Dis. 2007;66:222-7.

  33. Sturgess A, Edmonds J. Improving the effectiveness of autoantibody testing in the clinic. Autoimmun Rev. 2002;1:273-8.

  34. Mahler M, Meroni PL, Bossuyt X, Fritzler MJ. Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res [serie en Internet]. 2014 [citado 6 de Noviembre de 2016];2014(Article ID 315179). Disponible en: https://www.hindawi.com/journals/jir/2014/315179/

  35. Meroni PL, Biggioggero M, Pierangeli SS, Sheldon J, Zegers I, Borghi MO. Standardization of autoantibody testing: a paradigm for serology in rheumatic diseases. Nat Rev Rheumatol. 2014;10:35-43.

  36. Self SE. Autoantibody testing for autoimmune disease. Clin Chest Med. 2010;31:415-22.

  37. Sheldon J, Dellavance A. Strategies for building reference standards for autoantibodies. Front Immunol. 2015;6:194.

  38. Bizzaro N, Antico A, Platzgummer S, Tonutti E, Bassetti D, Pesente F, et al. Automated antinuclear immunofluorescence antibody screening: a comparative study of six computeraided diagnostic systems. Autoimmun Rev. 2013;13:292-8.

  39. Tozzoli R, D'Aurizio F, Villalta D, Bizzaro N. Automation, consolidation, and integration in autoimmune diagnostics. Autoimmun Highlights. 2015;6:1-6.

  40. Volkmann ER, Taylor M, Ben-Artzi A. Using the Antinuclear Antibody Test to Diagnose Rheumatic Diseases: When Does a Positive Test Warrant Further Investigation? South Med J. 2012;105:100-4.

  41. Bagnasco M, Grassia L, Pesce G. The management of the patient with unexpected autoantibody positivity. Autoimmun Rev. 2007;6:347-53.

  42. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. American College of Gastroenterology clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656-77.

  43. Wandstrat A, Carr-Johnson F, Branch V, Gray H, Fairhurst A, Reimold A, et al. Autoantibody profiling to identify individuals at risk systemic lupus erythematosus. J Autoimmun. 2006;27:153-60.

  44. Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol. 2009;15:325-9.

  45. Carlo Selmi C, Ceribelli A, Generali E, Scirè CA, Alborghetti F, Colloredo G, et al. Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15 years. Autoimmun Rev. 2016;15:162-6.

  46. Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ. Antinuclear, anticytoplasmic, and anti-Sjogren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol. 1985;36:120-8.

  47. Alves MF, Fraiji NA, Barbosa AC, De Lima DS, Souza JR, Dórea JG, et al. Fish consumption, mercury exposure and serum antinuclear antibody in Amazonians. Int J Environ Health Res. 2006;16:255-62.

  48. Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I . The significance of autoantibodiesin non-Hodgkin's lymphoma. Leuk Lymphoma. 2000;40:119-22.

  49. Berlin T, Zandman-Goddard G, Blank M, Matthias T, Pfeiffer S, Weis I, et al. Autoantibodies in non autoimmune individuals during infections. Ann N Y Acad Sci. 2007;1108:584-93.

  50. Abeles AM, Abeles M. The clinical utility of a positive antinuclear antibody test result. Am J Med. 2013;126:342-8.

  51. Metcalf JV, Mitchison HC, Palmer JM, Jones DE, Bassendine MF, James OF. Natural history of early primary biliary cirrhosis. Lancet. 1996;348:1399-402.

  52. Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis. 2005;64:1731-6.

  53. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.

  54. Hu ZD, Deng AM. Autoantibodies in pre-clinical autoimmune disease. Clin Chim Acta. 2014;437:14-8.

  55. Jones DE. Autoantigens in primary biliary cirrhosis. J Clin Pathol. 2000;53:813-21.

  56. Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Salvatore S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Ann Rheum Dis. 2011;70:1083-6.

  57. Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med. 2016. DOI 10.1007/s10238-016-0430-5.

  58. Legault KJ, Ugarte A, Crowther MA, Ruiz-Irastorza G . Prevention of recurrent thrombosis in antiphospholipidsyndrome: different from the general population? Curr Rheumatol Rep. 2016;18:26.

  59. Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105:2520-4.

  60. Nakazawa H, Makishima H, Ito T, Ota H, Momose K, Sekiguchi N, et al. Screening tests using serum tissue transglutaminase IgA may facilitate the identification of undiagnosed celiac disease among Japanese population. Int J Med Sci. 2014;11:819-23.

  61. Tonutti E, Bizzaro N .Diagnosis and classification of celiac disease and gluten sensitivity. Autoimmun Rev. 2014;13:472-6.

  62. Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63:1210-28.




2020     |     www.medigraphic.com